644 related articles for article (PubMed ID: 25378092)
1. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.
Mozaffari S; Abdolghaffari AH; Nikfar S; Abdollahi M
Hum Exp Toxicol; 2015 May; 34(5):445-59. PubMed ID: 25378092
[TBL] [Abstract][Full Text] [Related]
2. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
3. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.
Casanova MJ; Chaparro M; Domènech E; Barreiro-de Acosta M; Bermejo F; Iglesias E; Gomollón F; Rodrigo L; Calvet X; Esteve M; García-Planella E; García-López S; Taxonera C; Calvo M; López M; Ginard D; Gómez-García M; Garrido E; Pérez-Calle JL; Beltrán B; Piqueras M; Saro C; Botella B; Dueñas C; Ponferrada A; Mañosa M; García-Sánchez V; Maté J; Gisbert JP
Am J Gastroenterol; 2013 Mar; 108(3):433-40. PubMed ID: 23318480
[TBL] [Abstract][Full Text] [Related]
4. Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION).
Luu M; Benzenine E; Doret M; Michiels C; Barkun A; Degand T; Quantin C; Bardou M
Am J Gastroenterol; 2018 Nov; 113(11):1669-1677. PubMed ID: 29961771
[TBL] [Abstract][Full Text] [Related]
5. Association between Thiopurines Use and Pregnancy Outcomes in Female Patients with Inflammatory Bowel Disease: A Meta-Analysis.
Zhang Y; Li D; Guo H; Wang W; Li X; Shen S
Curr Pharm Des; 2021; 27(19):2317-2324. PubMed ID: 32938343
[TBL] [Abstract][Full Text] [Related]
6. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.
Kanis SL; Modderman S; Escher JC; Erler N; Beukers R; de Boer N; Bodelier A; Depla ACTM; Dijkstra G; van Dijk ARM; Gilissen L; Hoentjen F; Jansen JM; Kuyvenhoven J; Mahmmod N; Mallant-Hent RC; van der Meulen-de Jong AE; Noruzi A; Oldenburg B; Oostenbrug LE; Ter Borg PCJ; Pierik M; Romberg-Camps M; Thijs W; West R; de Lima A; van der Woude CJ;
Gut; 2021 Jul; 70(7):1266-1274. PubMed ID: 33046558
[TBL] [Abstract][Full Text] [Related]
7. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease.
Mahadevan U; Long MD; Kane SV; Roy A; Dubinsky MC; Sands BE; Cohen RD; Chambers CD; Sandborn WJ;
Gastroenterology; 2021 Mar; 160(4):1131-1139. PubMed ID: 33227283
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study.
Coelho J; Beaugerie L; Colombel JF; Hébuterne X; Lerebours E; Lémann M; Baumer P; Cosnes J; Bourreille A; Gendre JP; Seksik P; Blain A; Metman EH; Nisard A; Cadiot G; Veyrac M; Coffin B; Dray X; Carrat F; Marteau P;
Gut; 2011 Feb; 60(2):198-203. PubMed ID: 21115547
[TBL] [Abstract][Full Text] [Related]
9. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease.
Akbari M; Shah S; Velayos FS; Mahadevan U; Cheifetz AS
Inflamm Bowel Dis; 2013 Jan; 19(1):15-22. PubMed ID: 22434610
[TBL] [Abstract][Full Text] [Related]
10. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
11. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy.
Hutson JR; Matlow JN; Moretti ME; Koren G
J Obstet Gynaecol; 2013 Jan; 33(1):1-8. PubMed ID: 23259868
[TBL] [Abstract][Full Text] [Related]
12. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety.
de Lima A; Zelinkova Z; van der Ent C; Steegers EA; van der Woude CJ
Gut; 2016 Aug; 65(8):1261-8. PubMed ID: 25966992
[TBL] [Abstract][Full Text] [Related]
13. Use of Thiopurines During Conception and Pregnancy Is Not Associated With Adverse Pregnancy Outcomes or Health of Infants at One Year in a Prospective Study.
Kanis SL; de Lima-Karagiannis A; de Boer NKH; van der Woude CJ
Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1232-1241.e1. PubMed ID: 28342949
[TBL] [Abstract][Full Text] [Related]
14. Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis.
Wang H; Hu Y; Chen F; Shen M
BMC Pregnancy Childbirth; 2022 Nov; 22(1):854. PubMed ID: 36402978
[TBL] [Abstract][Full Text] [Related]
15. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review.
Nielsen OH; Loftus EV; Jess T
BMC Med; 2013 Jul; 11():174. PubMed ID: 23902720
[TBL] [Abstract][Full Text] [Related]
16. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications.
Ban L; Tata LJ; Fiaschi L; Card T
Gastroenterology; 2014 Jan; 146(1):76-84. PubMed ID: 24126096
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study.
Bortlik M; Machkova N; Duricova D; Malickova K; Hrdlicka L; Lukas M; Kohout P; Shonova O; Lukas M
Scand J Gastroenterol; 2013 Aug; 48(8):951-8. PubMed ID: 23834232
[TBL] [Abstract][Full Text] [Related]
18. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
Gómez-García M; Cabello-Tapia MJ; Sánchez-Capilla AD; De Teresa-Galván J; Redondo-Cerezo E
World J Gastroenterol; 2013 Aug; 19(30):4877-86. PubMed ID: 23946592
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study.
Chaparro M; Verreth A; Lobaton T; Gravito-Soares E; Julsgaard M; Savarino E; Magro F; Biron AI; Lopez-Serrano P; Casanova MJ; Gompertz M; Vitor S; Arroyo M; Pugliese D; Zabana Y; Vicente R; Aguas M; Shitrit BA; Gutierrez A; Doherty GA; Fernandez-Salazar L; Cadilla MJ; Huguet JM; OʼToole A; Stasi E; Marcos MN; Villoria A; Karmiris K; Rahier JF; Rodriguez C; Palomares DM; Fiorino G; Benitez JM; Principi M; Naftali T; Taxonera C; Mantzaris G; Sebkova L; Iade B; Lissner D; Bradley FI; Roman LA; Marin-Jimenez I; Merino O; Sierra M; Van Domselaar M; Caprioli F; Guerra I; Peixe P; Piqueras M; Rodriguez-Lago I; Ber Y; van Hoeve K; Torres P; Gravito-Soares M; Rudbeck-Resdal D; Bartolo O; Peixoto A; Martin G; Armuzzi A; Garre A; Donday MG; de Carpi MFJ; Gisbert JP
Am J Gastroenterol; 2018 Mar; 113(3):396-403. PubMed ID: 29460920
[TBL] [Abstract][Full Text] [Related]
20. Safe and effective: anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis.
Kiely CJ; Subramaniam K; Platten J; Pavli P
Intern Med J; 2016 May; 46(5):616-9. PubMed ID: 27170239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
